Palliative Sedation for the Terminally Ill Patient

Area of Science:

• Palliative Care
• Medical Ethics
• Pharmacology

Background:

• Palliative sedation (PS) is a medical intervention for terminally ill patients with refractory symptoms.
• Proportional PS, titrating drugs to the minimum effective dose, is the most common approach.
• Prevalence varies by care setting, with 25-33% of terminally ill patients receiving PS.

Purpose of the Study:

• To define palliative sedation and its application in managing refractory symptoms.
• To differentiate PS from euthanasia and outline decision-making processes.
• To identify common symptoms managed by PS and effective pharmacological agents.

Main Methods:

• Literature review and synthesis of current practices in palliative sedation.
• Analysis of symptom prevalence and drug efficacy in PS.
• Comparison of PS with other end-of-life care interventions.

Main Results:

• Refractory symptoms like delirium and dyspnea are primary indications for PS.
• Continuous deep sedation is required in a quarter of patients undergoing PS.
• Midazolam and haloperidol are frequently used for refractory delirium; other neuroleptics are also effective.

Conclusions:

• Palliative sedation effectively manages unbearable suffering from refractory symptoms in the final hours or days of life.
• Patient consensus and advanced care planning are vital for ethical PS implementation.
• PS is distinct from euthanasia in intent, procedure, and outcome, with no detrimental effect on survival.